Walter M. Stadler to Patient Compliance
This is a "connection" page, showing publications Walter M. Stadler has written about Patient Compliance.
Connection Strength
0.022
-
A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):87-92.
Score: 0.022